𝔖 Bobbio Scriptorium

✦ LIBER ✦

523 Effect of ALT flares on efficacy and safety of peginterferon α-2a (40 kDa) (PEGASYS®), peginterferon α-2a plus lamivudine and lamivudine in HBeAg-positive chronic hepatitis B (CHB)

Book ID: 117374031
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 253 KB
Volume: 42
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(05)81934-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

31 Peginterferon α-2a (40 kDa) (PEGASYS®

31 Peginterferon α-2a (40 kDa) (PEGASYS®) versus peginterferon α-2a plus lamivudine versus lamivudine in HBeAg-positive chronic HBV: Effect of previous treatment and drug exposure on sustained response

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 105 KB

484 On-treatment predictors of sustained

484 On-treatment predictors of sustained biochemical and virological response in patients with HBeAg-negative chronic hepatitis B (CHB) treated with peginterferon α-2a (40 kDa) (PEGASYS®)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 135 KB

71 Effect of genotype and other baseline

71 Effect of genotype and other baseline factors on response to peginterferon α-2a (40 kDa) (PEGASYS®) in HBeAg-positive chronic hepatitis B: Results from a large, randomised study

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 239 KB

Evidence for the efficacy of peginterfer

Evidence for the efficacy of peginterferon alfa-2a (40 KD) (PEGASYS) in the treatment of HBeAg-positive chronic hepatitis B (CHB) and impact of baseline factors

✍ W.Graham E. Cooksley; Teerha Piratvisuth; Yuan-Jen Wang; Varocha Mahachai; You-C 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 165 KB

95 Peginterferon alfa-2A (40KD) (PEGASYS

95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine

✍ P. Marcellin; G.K.K. Lau; F. Bonino; P. Farci; S. Hadziyannis; R. Jin; Z.-M. Lu; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 64 KB

421 A new bio-mathematical model to desc

421 A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBEAG-negative/anti-HBE-positive chronic hepatitis B patients treated with peginterferon alfa-2A (40KD) (PEGASYS®), lamivudine, or PEGASYS® plus lamivudine combin

✍ P. Colombatto; R. Bizzarri; L. Civitano; F. Oliveri; F. Bonino; G. Germanidis; P 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 64 KB